sb 203580 has been researched along with cgp 57380 in 5 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (cgp 57380) | Trials (cgp 57380) | Recent Studies (post-2010) (cgp 57380) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 64 | 0 | 44 |
| Protein | Taxonomy | sb 203580 (IC50) | cgp 57380 (IC50) |
|---|---|---|---|
| Serine/threonine-protein kinase Sgk1 | Homo sapiens (human) | 2.7 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 3 | Homo sapiens (human) | 3.2 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 1.6 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 2.5 | |
| Eukaryotic translation initiation factor 4E | Homo sapiens (human) | 3 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.6 | |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | 5 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.51 | |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | 1.1 | |
| Aurora kinase B | Homo sapiens (human) | 2.5 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 1.2182 | |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 2.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Morley, SJ; Naegele, S | 1 |
| Cherla, RP; Lee, SY; Mees, PL; Tesh, VL | 1 |
| Frost, P; Fukunaga, R; Gera, J; Hoang, B; Lichtenstein, A; Shi, Y; Yang, Y | 1 |
5 other study(ies) available for sb 203580 and cgp 57380
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Phosphorylation of initiation factor 4E is resistant to SB203580 in cells expressing a drug-resistant mutant of stress-activated protein kinase 2a/p38.
Topics: Aniline Compounds; Arsenites; Cell Line; Chromones; Drug Resistance; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Morpholines; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Purines; Pyridines; Signal Transduction; Stress, Physiological | 2003 |
Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line.
Topics: Aniline Compounds; Anisomycin; Anthracenes; Cell Line, Tumor; Cytokines; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Flavonoids; Humans; Imidazoles; Lipopolysaccharides; Macrophages; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphorylation; Purines; Pyridines; RNA, Messenger; Shiga Toxin 1; Time Factors | 2006 |
MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Topics: 5' Untranslated Regions; Aniline Compounds; Animals; Butadienes; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Genes, myc; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Mice; Multiple Myeloma; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Purines; Pyridines; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation | 2013 |